Evidence map›Paper›PMID 36250288›Full record

ArticleVox sanguinis2022

Incidence and risk factors for graft failure in the modern era of cord blood transplantation.

Jennifer Holter Chakrabarty, Joshua Glover, Sara Schmidt, Minh Phan, Michelle Bycko, Quyen Duong, Sara K Vesely, Caroline O'Neal, Chelsie Robertson, Christina Davis and 6 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vox sanguinis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Jennifer Holter ChakrabartyStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.ORCID https://orcid.org/0000-0003-1425-7002
Joshua GloverStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.ORCID https://orcid.org/0000-0001-5030-1563
Sara SchmidtStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Minh PhanStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Michelle ByckoStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Quyen DuongStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Sara K VeselyHudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.ORCID https://orcid.org/0000-0003-3448-0156
Caroline O'NealStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Chelsie RobertsonStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Christina DavisStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Kristen KratochvilStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Carrie YuenStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Mohamad KhawandanahStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
George SelbyStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Rami JassimStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Kirsten M WilliamsAflac Cancer and Blood Disorders, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA.
University of Oklahoma Health Sciences Center · USEmory University · US

Funding

Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Michael S. Businelle · 2018 to 2026
$27.1M
Imaging and Blood Biomarkers to Predict Graft Failure after HSCTR01HL146668 · NHLBI · EMORY UNIVERSITY · PI HOLTER CHAKRABARTY, JENNIFER LIN, WILLIAMS, KIRSTEN · 2019 to 2023
$2.9M
5R01HL146668-03NCI NIH HHS P30 CA225520NHLBI NIH HHS R01 HL146668US National Cancer Institute P30CA225520
6 · The paper itself

Abstract

BACKGROUND AND

objectivesGraft failure (GF) after cord blood transplant (CBT) has decreased with improved supportive care and cord selection strategies. We aimed to evaluate cord blood selection and factors associated with retransplantation on the incidence of GF, determine risk factors for GF including host antibodies to Kell antigen and evaluate survival after GF. MATERIALS AND

methodsWe retrospectively reviewed 84 patients who underwent CBT at the University of Oklahoma between 2000 and 2016 and compared outcomes in patients with/without engraftment by Day 28. The nonengraftment cohort was further divided into patients who underwent retransplantation. Kaplan-Meier curves with log-rank tests were calculated to assess the association between mortality and engraftment.

resultsEngraftment following CBT was high at 81%, with 52% engrafting by Day 28 and an additional 29% engrafting by a median of 36 days. Retransplantation led to 88% engraftment at a median of 53 days. Overall, 75% of the 40 patients who did not engraft by Day 28 died. Female sex and total nucleated cell count < 3.5/kg were significantly associated with lack of engraftment and higher mortality. Antibodies to Kell fetal antigen were not identified. Retransplantation by Day 28 for primary GF conferred a survival advantage.

conclusionThis study demonstrates that failure to engraft by 28 days was associated with increased mortality, and risk was mitigated with early retransplantation. Female sex and low total cell dose were associated with increased mortality. Early identification of GF coupled with early retransplantation can reduce mortality in CBT.

Indexed as

Cord Blood Stem Cell TransplantationGraft vs Host DiseaseHematopoietic Stem Cell TransplantationFemaleGraft SurvivalHumansRetrospective StudiesRisk Factorscord blood transplantgraft failurehaematopoietic stem cellprogenitor celltransplantation

Identifiers

PMID36250288
PMCPMC9772075
OpenAlexW4306398803

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.